PL399787A1 - Krysztaly (R)- lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu, kompozycja farmaceutyczna zawierajaca te krysztaly i ich zastosowanie - Google Patents

Krysztaly (R)- lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu, kompozycja farmaceutyczna zawierajaca te krysztaly i ich zastosowanie

Info

Publication number
PL399787A1
PL399787A1 PL399787A PL39978701A PL399787A1 PL 399787 A1 PL399787 A1 PL 399787A1 PL 399787 A PL399787 A PL 399787A PL 39978701 A PL39978701 A PL 39978701A PL 399787 A1 PL399787 A1 PL 399787A1
Authority
PL
Poland
Prior art keywords
crystals
methyl
lansoprazole
trifluoroethoxy
sulfinyl
Prior art date
Application number
PL399787A
Other languages
English (en)
Inventor
Hideo Hashimoto
Tadashi Urai
Original Assignee
Takeda Pharmaceutical Company Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18838123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL399787(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Ltd. filed Critical Takeda Pharmaceutical Company Ltd.
Publication of PL399787A1 publication Critical patent/PL399787A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL399787A 2000-12-01 2001-11-30 Krysztaly (R)- lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu, kompozycja farmaceutyczna zawierajaca te krysztaly i ich zastosowanie PL399787A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000367757 2000-12-01

Publications (1)

Publication Number Publication Date
PL399787A1 true PL399787A1 (pl) 2012-11-05

Family

ID=18838123

Family Applications (3)

Application Number Title Priority Date Filing Date
PL399787A PL399787A1 (pl) 2000-12-01 2001-11-30 Krysztaly (R)- lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu, kompozycja farmaceutyczna zawierajaca te krysztaly i ich zastosowanie
PL362801A PL214684B1 (pl) 2000-12-01 2001-11-30 Sposób wytwarzania krysztalów (R) lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu
PL409463A PL409463A1 (pl) 2000-12-01 2001-11-30 Kryształy (R) lub (S)-2-[[[3-metylo-4(2,2,2-trifluoroetoksy)-2-pirydynylo] metylo] sulfinylo]-1H-benzimidazolu, kompozycja farmaceutyczna zawierająca te kryształy i ich zastosowanie oraz sposób ich stabilizacji

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL362801A PL214684B1 (pl) 2000-12-01 2001-11-30 Sposób wytwarzania krysztalów (R) lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu
PL409463A PL409463A1 (pl) 2000-12-01 2001-11-30 Kryształy (R) lub (S)-2-[[[3-metylo-4(2,2,2-trifluoroetoksy)-2-pirydynylo] metylo] sulfinylo]-1H-benzimidazolu, kompozycja farmaceutyczna zawierająca te kryształy i ich zastosowanie oraz sposób ich stabilizacji

Country Status (17)

Country Link
US (2) US7285668B2 (pl)
EP (2) EP1337525B8 (pl)
KR (3) KR20100002278A (pl)
CN (1) CN1254473C (pl)
AT (1) ATE511508T1 (pl)
AU (1) AU2002218506A1 (pl)
CA (1) CA2436825C (pl)
CY (1) CY1112347T1 (pl)
DK (1) DK1337525T3 (pl)
ES (1) ES2367419T3 (pl)
HK (1) HK1054380B (pl)
HU (1) HU229356B1 (pl)
NO (1) NO326019B1 (pl)
PL (3) PL399787A1 (pl)
PT (1) PT1337525E (pl)
TW (1) TWI290922B (pl)
WO (1) WO2002044167A1 (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020027315A1 (en) * 2000-03-10 2002-03-07 Parker Gerard E. Low-firing temperature method for producing Al2O3 bodies having enhanced chemical resistance
ES2511774T3 (es) 2000-05-15 2014-10-23 Takeda Pharmaceutical Company Limited Formas cristalinas de (R)-lansoprazol
KR20040093187A (ko) * 2002-03-27 2004-11-04 테바 파마슈티컬 인더스트리즈 리미티드 란소프라졸 다형 및 그것의 제조 방법
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
AU2004207720A1 (en) * 2003-01-31 2004-08-12 Teijin Pharma Limited Crystal of (23S)-1alpha-hydroxy-27-nor-25-methylenevitamin D3-26,23-lactone and process for producing the same
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
AR045061A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
EP1681056A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
CN101389316A (zh) 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
KR100758600B1 (ko) * 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
JP5366558B2 (ja) 2006-12-28 2013-12-11 武田薬品工業株式会社 口腔内崩壊性固形製剤
WO2008087665A2 (en) * 2007-01-18 2008-07-24 Matrix Laboratories Ltd Process for preparation of lansoprazole
KR101303813B1 (ko) 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
CN102014638A (zh) * 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
NZ585944A (en) * 2007-12-18 2011-11-25 Watson Pharma Private Ltd A process for preparation of stable amorphous R-(+)-lansoprazole
JP2011513202A (ja) 2008-03-10 2011-04-28 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
NZ589150A (en) * 2008-05-14 2012-03-30 Watson Pharma Private Ltd Stable r (+) -lansoprazole amine salt and a process for preparing the same
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
WO2010056059A2 (en) * 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
WO2010095144A2 (en) * 2009-02-04 2010-08-26 Msn Laboratories Limited Process for the preparation of proton pump inhibitors
IT1392813B1 (it) * 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
US20130197232A1 (en) 2010-01-29 2013-08-01 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
WO2011121548A1 (en) 2010-03-31 2011-10-06 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CA2795056C (en) 2010-03-31 2015-03-24 Ranbaxy Laboratories Limited Salts of dexlansoprazole and their preparation
WO2012001705A2 (en) 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
KR101908748B1 (ko) 2010-12-03 2018-10-16 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴정
SG10201602311XA (en) 2010-12-27 2016-04-28 Takeda Pharmaceutical Orally disintegrating tablet
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2012176140A1 (en) 2011-06-21 2012-12-27 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
EP2785331B1 (en) 2011-11-30 2015-11-18 Takeda Pharmaceutical Company Limited Dry coated tablet
IN2014CN04228A (pl) 2011-12-29 2015-07-17 Intel Corp
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
CN105392486A (zh) 2013-05-21 2016-03-09 武田药品工业株式会社 口腔崩解片
CN103254174B (zh) * 2013-06-05 2014-06-11 湖北济生医药有限公司 一种兰索拉唑化合物及其药物组合物
US9920196B2 (en) 2013-06-20 2018-03-20 Japan Polypropylene Corporation Propylene-based block copolymer
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN104997739A (zh) * 2015-08-31 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物兰索拉唑组合物冻干粉针剂
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN106279107A (zh) * 2016-08-10 2017-01-04 成都尚药科技有限公司 一种右旋兰索拉唑晶型的制备方法
CN106749182A (zh) * 2016-11-08 2017-05-31 山东裕欣药业有限公司 一种右旋兰索拉唑晶型化合物及其制备方法
IT201700050223A1 (it) 2017-05-09 2018-11-09 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
JPH1085502A (ja) * 1996-09-19 1998-04-07 Konica Corp 晶析方法
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
CN1238694A (zh) * 1996-11-22 1999-12-15 普罗克特和甘保尔公司 治疗肠胃病用的含铋和nsaid的组合物
WO1999038512A1 (en) * 1998-01-30 1999-08-05 Sepracor Inc. S-lansoprazole compositions and methods
JP4536905B2 (ja) * 1999-06-17 2010-09-01 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
DE60020967T2 (de) * 1999-06-30 2006-05-04 Takeda Pharmaceutical Co. Ltd. Kristalle von lansoprazole
JP2001039975A (ja) * 1999-07-26 2001-02-13 Eisai Co Ltd スルホキシド誘導体の結晶およびその製造法
WO2001014366A1 (fr) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Procede de preparation de derives optiquement actifs de sulfoxyde
AU2001252595A1 (en) 2000-04-28 2001-11-12 Takeda Chemical Industries Ltd. Process for producing optically active sulfoxide derivative
ES2511774T3 (es) 2000-05-15 2014-10-23 Takeda Pharmaceutical Company Limited Formas cristalinas de (R)-lansoprazol
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法

Also Published As

Publication number Publication date
EP1337525B8 (en) 2011-10-05
DK1337525T3 (da) 2011-09-19
TWI290922B (en) 2007-12-11
KR20030060967A (ko) 2003-07-16
KR100939948B1 (ko) 2010-02-04
NO20032437L (no) 2003-07-17
PL362801A1 (pl) 2004-11-02
HUP0400781A2 (hu) 2004-07-28
US20040049045A1 (en) 2004-03-11
CA2436825A1 (en) 2002-06-06
KR20090003348A (ko) 2009-01-09
KR20100002278A (ko) 2010-01-06
ATE511508T1 (de) 2011-06-15
CY1112347T1 (el) 2015-12-09
EP1337525B1 (en) 2011-06-01
EP2345650A1 (en) 2011-07-20
PT1337525E (pt) 2011-09-01
WO2002044167A1 (en) 2002-06-06
PL409463A1 (pl) 2016-02-15
KR100887912B1 (ko) 2009-03-12
PL214684B1 (pl) 2013-09-30
HK1054380B (zh) 2012-01-27
NO326019B1 (no) 2008-09-01
HU229356B1 (en) 2013-11-28
HK1054380A1 (pl) 2003-11-28
CA2436825C (en) 2011-01-18
ES2367419T3 (es) 2011-11-03
HUP0400781A3 (en) 2010-03-29
US7285668B2 (en) 2007-10-23
NO20032437D0 (no) 2003-05-28
CN1254473C (zh) 2006-05-03
AU2002218506A1 (en) 2002-06-11
CN1478086A (zh) 2004-02-25
US20080306118A1 (en) 2008-12-11
EP1337525A1 (en) 2003-08-27

Similar Documents

Publication Publication Date Title
PL399787A1 (pl) Krysztaly (R)- lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu, kompozycja farmaceutyczna zawierajaca te krysztaly i ich zastosowanie
HK1038227A1 (en) Crystalline form of (r)-2-ÄÄÄ3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylÜmethylÜsulfinylÜ-1h-benzimidazole
EP1897877A3 (en) Process for producing crystal
DE60020967D1 (de) Kristalle von lansoprazole
RU95105587A (ru) Оптически чистые соединения пиридинилметил сульфинил-1н-бензимидазола, их соли, способы получения, фармкомпозиция, способ лечения
YU53801A (sh) Kalijumova so (s) - omeprazola
DK0624595T3 (da) Nor-galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
TR200101282T2 (tr) Omeprozolün yeni kristalli formu
HUP0302480A3 (en) Pyridinone derivatives for treatment of atherosclerosis, process for preparation thereof and pharmaceutical compositions containing the same
IL145958A0 (en) Polymorphic form of arginine salt of (2s)-3-[4-[2-phenoxazin-10-yl)ethoxy] phenyl]2-ethoxypropanoic acid, processes for the preparation thereof and pharmaceutical compositions containing the same
NO319782B1 (no) Pantoprazol-magnesiumdihydrat, medikamenter inneholdende denne og anvendelsen derav
NO20022558L (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
EP0179430A3 (en) Aqueous pharmaceutical formulations of piroxicam monohydrate
HUP0203444A3 (en) Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, process for its preparation, pharmaceutical composition containing it and use thereof
HUP0300389A2 (hu) A kabergolin II. kristályformája, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
HUP0204394A2 (en) Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
HUP0102523A2 (hu) Javított eljárás 5-metoxi-2-[(4-metoxi-3,5-dimetil-2-piridil)-metil]-szulfinil-1H-benzimidazol előállítására
DK165322C (da) Derivater af 4,5-dihydrooxazolyl-2-oe(2-pyridyl)-methylthioaa-benzimidazoler eller -thienoimidazoler, fremgangsmaade til fremstilling heraf og farmaceutiske praeparater indeholdende saadanne derivater
PT87690A (pt) Process for the preparation of acaricide formulations comprising 3,6-bis[2-chlorine-phenyl)-1,2,4,5-tetrazin-(clophenthezine)and oxide of bis[tris(2-methyl-3-phenyl-propyl)tin]oxide of penbutatin
HUP0303676A2 (hu) Helyettesített 4-fenil-1-(1-fenil-ciklohexil)-1,2,3,6-tetrahidropiridinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE60003031D1 (de) Benzo[f]naphthyridinderivate, ihre herstellung und sie enthaltende pharmazeutische zusammenstzungen
EP1284287A4 (en) METHOD FOR PRODUCING A VIRUS VECTOR
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
TH57580B (th) วิธีการผลิตผลึก
HU0100751D0 (en) New aryl or heteroaryl quinolinylphosphonic acid derivatives, process for their preparation and pharmaceutical compositions containing them